The Mainz-based company Biontech $BNTX (+0,73 %) is currently testing several active substances in phase 2 trials - but none have yet reached the lengthy phase 3 required for approval.
US competitor Moderna $MRNA (+5,16 %) claims to have an active substance - mRNA-4157 - in two phase 3 trials: as an add-on therapy against melanoma and against a certain form of lung cancer, non-small cell lung cancer (NSCLC).
The Moderna preparation mRNA-4157 (V940) could in turn be approved in the foreseeable future for the treatment of melanoma.
The active ingredient is currently being tested in two phase 3 trials - against a form of lung cancer and against high-risk melanoma. In fact, the US Food and Drug Administration nach Angaben von Moderna und Merck has announced an accelerated approval process for the drug in combination with the immune checkpoint inhibitor pembrolizumab for melanoma therapy.
https://www.n-tv.de/wissen/Krebs-koennte-mit-mRNA-Praeparaten-besiegt-werden-article25509772.html
